INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 80 filers reported holding INOZYME PHARMA INC in Q4 2023. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $837,762 | +62842.3% | 187,839 | +8.1% | 0.00% | -50.0% |
| Q1 2024 | $1,331 | +43.0% | 173,700 | -20.5% | 0.00% | +100.0% |
| Q4 2023 | $931 | -25.0% | 218,500 | -26.1% | 0.00% | -50.0% |
| Q3 2023 | $1,242 | -6.8% | 295,608 | +23.6% | 0.00% | 0.0% |
| Q2 2023 | $1,332 | +25.0% | 239,200 | +28.5% | 0.00% | +100.0% |
| Q1 2023 | $1,066 | +291.9% | 186,100 | -28.1% | 0.00% | – |
| Q4 2022 | $272 | -99.9% | 258,900 | +66.6% | 0.00% | -100.0% |
| Q3 2022 | $416,000 | -26.2% | 155,400 | +31.4% | 0.00% | 0.0% |
| Q2 2022 | $564,000 | +1051.0% | 118,300 | +894.1% | 0.00% | – |
| Q1 2022 | $49,000 | – | 11,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $27,113,000 | 10.69% |
| Burrage Capital Management LLC | 242,517 | $4,132,000 | 4.14% |
| CHI Advisors LLC | 927,264 | $15,801,000 | 3.68% |
| Sofinnova Investments, Inc. | 2,028,308 | $34,562,000 | 1.99% |
| Novo Holdings A/S | 1,867,706 | $31,826,000 | 1.41% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,178,985 | $37,130,000 | 0.66% |
| RA Capital Management | 2,003,653 | $34,142,000 | 0.55% |
| NEA Management Company, LLC | 2,444,379 | $41,652,000 | 0.54% |
| Rock Springs Capital Management LP | 840,272 | $14,318,000 | 0.28% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 365,172 | $6,223,000 | 0.09% |